Use of a compound of dihidroimidazo 2.3 - [1,2-c] quinazoline or a Pharmaceutical composition containing the same as active Agent only, or a combination of said Pharmaceutical composition) or a compound containing Said compound and (b) one or more active agents, additionalFor the preparation of a Medicament for the Treatment or prophylaxis of cancer； combinations of said Compound (a) and (b) one or more additional Active agents； a Pharmaceutical composition comprising Said Compound as an active agent for the treatment of breast cancer； com Pharmaceutical Combination comprising a position of said Compound (a) and (b) one or more active agents AdIcionales； use of biomarkers involved in the modification of the expression of BCL, expression and / or Activation of signalling by her family, PIK3CA and / or loss of PTEN to predict Sensitivity and / or Resistance of the compound to a patient with Cancer and provide a winning Combination Synergistic n based on Reason, as defined in the present,To increase the sensitivity and / or to overcome resistance, and a method to determine the level of a component of one or more expression of BCL, expression and / or Activation of signalling by her family, PIK3CA and / or loss of PTEN.Claim 8: a combination of: a) a compound of 2, 3 - dihidroimidazo [1,2-c] quinazoline according to any one of claims 1 to 7, or a Salt, solvate, hydrate or physiologically acceptable stereoisomer thereof； and a Pharmaceutical composition containing such a compound or Na Salt, solvate, hydrate or physiologically acceptable stereoisomer thereof,And (b) one or more active agents selected from the Group further comprises: an inhibitor of BCL as abt-737, abt-263 (navitoclax), em20 - 25, yc137, GX - 015 - 070 (obatoclax) tetrocarcin, UCB 1350883, at-101 ((-) - gossypol), SPC (beclanorsen - 2004), IG - 105, WL - 276, Bi 97c1 VRL (Immuno -, I - Vivorelbine (DATS), allitridin - 103 (CNDO), apogossypol), D - G - 3139 (Genasense), Evotec, GDP - 1402,EU - 517,
